Taniyama M, Suzuki Y, Enomoto S et al (1995) Specific
PCR amplification for detection of the mutation of mitochondrial DNA in diabetic patients. J Japan Diab Response from the author Dear Sir, The pathogenic mutation in mitochondrial DNA at position 3243 exhibits enigmatic properties when its phenotypic expression is considered. Many carriers of this mutation develop mitochondrial diabetes and deafness (MIDD). In contrast, other carriers of the 3243 mutation develop the severe neurological syndrome of MELAS [1, 2] . The data presented by Suzuki and collaborators in their letter and in their previous publication [3] indicate the association of inactive ALDH2 with the 3243 mutation in patients with mitochondrial diabetes. Remarkably, this association is absent in patients with MELAS. The authors suggest that the expected accumulation of acetaldehyde in carriers of inactive ALDH2 may be a factor in developing a diabetic phenotype. In addition, the authors propose that high heteroplasmy levels of the 3243 mutation may favour the development of MELAS. Though the data are interesting a note of caution is warranted with respect to genetic association studies. They are vulnerable to misinterpretation when the study groups are not fully matched for genetic background. The presented data are based on allele frequencies of mutant ALDH2 in a group of MELAS patients and a group of diabetic patients with the 3243 mutation. For comparison, the authors have included a large control group of non-3243 carriers. Because of the intrinsic situation of relatively small numbers of 3243 carriers in each group, which are obtained through clinics, it is difficult to find groups of 3243 carriers fully matched to the control group. Besides, spurious relationships may be present in selected patients from a specific geographical region. Despite this word of caution, the results by Suzuki and collaborators are certainly of interest and will trigger studies in other populations. An aspect on which different points of view exist is whether variations in heteroplasmy levels alone are responsible for the development of the MELAS phenotype. Studies have shown clustering of MELAS in only some pedigrees with the 3243 mutation. Other studies found no clear relation between the phenotype and heteroplasmy levels and this has led to the hypothesis proposed by Odawara and Yamashita [4] that additional factors are required for the development of MELAS. Heteroplasmy levels are generally determined on a population of cells in a tissue sample from patients. Studies by Matthews et al. [5] have provided evidence that there is variation of heteroplasmy between individual cells which is not adequately reflected by the mean heteroplasmy value for a particular tissue. These authors suggested that the distribution of the mutation over individual cells rather than the overall level of heteroplasmy may contribute to the development of the clinical phenotype. The existence of large differences in heteroplasmy levels between individual cells has been corroborated [6] by direct visualization of mutant mtDNA in individual cells by fluorescence in situ hybridization. It is my feeling that heterogeneity in heteroplasmy of the 3243 mutation at the level of individual cells has to be taken into consideration for the evaluation of phenotype-genotype relations.
Yours sincerely, J. A. Maassen
